Key Takeaway
The right blood work on GLP-1 tells you what the scale cannot: whether your metabolic health is actually improving. This blood work GLP-1 labs resource covers the essential information you need to make informed decisions.
The right blood work on GLP-1 tells you what the scale cannot: whether your metabolic health is actually improving. This blood work GLP-1 labs resource covers the essential information you need to make informed decisions. Lab results confirm that your medication is working at the cellular level, catch nutritional deficiencies before they cause problems, and guide dose adjustments.
Key Takeaways: - Baseline Labs (Before Starting) - Follow-Up Lab Schedule - Key Results to Watch
This guide covers exactly which labs you need and when.
Baseline Labs (Before Starting)
Get these before your first injection to establish your starting point:
- HbA1c and fasting glucose: Your metabolic baseline. GLP-1 medications improve these markers.
- Fasting insulin: More sensitive measure of insulin resistance than glucose alone.
- Complete metabolic panel (CMP): Liver and kidney function, electrolytes. Ensures your organs can process the medication safely.
- Lipid panel: Total cholesterol, LDL, HDL, triglycerides. GLP-1 medications often improve these.
- Thyroid panel (TSH): GLP-1 medications carry rare thyroid warnings. Baseline TSH is standard.
- Vitamin D, B12, iron, ferritin: Common deficiencies that worsen with reduced food intake.
- CBC (complete blood count): General health assessment.
Free Download: Doctor Report Template Lab tracking sheet with reference ranges, trending columns, and space for notes. Get yours free) we'll email it to you instantly. [Download Your Free Report Template]
Follow-Up Lab Schedule
Month 3: HbA1c, fasting glucose, CMP, lipid panel. First check to confirm medication is producing metabolic improvement.
Month 6: Full panel repeat including vitamins and minerals. Nutritional deficiencies may emerge by this point due to reduced calorie intake.
Every 6 months thereafter: Standard metabolic monitoring. More frequently if values are abnormal or dose changes are made.
Key Results to Watch
HbA1c improvement: Even small drops (0.3-0.5%) indicate meaningful metabolic improvement. Many GLP-1 users see drops of 1.0-2.0% or more.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Triglyceride reduction: Often improves significantly within 3-6 months. A strong indicator of cardiovascular risk reduction.
Vitamin deficiencies: B12, iron, and vitamin D are most likely to decline with reduced food intake. Supplement if levels drop below optimal ranges.
Liver enzymes: Should improve or remain stable. Elevated liver enzymes warrant further evaluation.
Track all lab results in the . Share trends with your .
Read about and .
Frequently Asked Questions
Will my insurance cover GLP-1-related blood work?
Most insurance covers standard metabolic labs ordered by your provider. The tests listed above are standard medical labs, not specialty tests.
What if my blood sugar is too low on GLP-1?
Hypoglycemia is uncommon with GLP-1 medications alone. If you are also on insulin or sulfonylureas, the risk increases. Report any blood sugar below 70 mg/dL to your provider.
Should I get blood work more often during dose increases?
Not necessarily for standard metabolic labs. However, if you have diabetes or pre-existing conditions, your provider may recommend more frequent monitoring during titration.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide (no pressure, no commitment.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24